These 5 stocks under $10 look poised to potentially trade higher. Arrowhead Pharmaceuticals (ARWR) , which develops novel drugs to treat intractable diseases in the U.S. has been destroyed by the sellers over the last six months, with shares collapsing by 66%. Another under-$10 biotechnology player that's starting to spike within range of triggering a big breakout trade is Aptevo Therapeutics (APVO) , which provides oncology and hematology therapeutics. Cerecor (CERC) which develops drugs to treat patients with neurological and psychiatric disorder has been destroyed by the sellers over the last six months, with shares plunging lower by 80%. Strongbridge Biopharma (SBBP) , which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases in the U.S. and internationally has been under heavy selling pressure over the last six months, with shares falling by 42%. Tahoe Resources (TAHO) , which explores, develops, and operates mines in the Americas has been smacked lower by the sellers over the last six months, with shares dropping sharply by 43.5%.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.